SBIR/STTR Research Award

Chliposome IFN-gamma-pDNA Naoparticle Therapy for Asthma

Award identifier e089f868009b436aca24d89a348229a9e9c28a7df6072898a8d08b02402e9bfdAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$110,023

Program and phase

STTR · Phase I

Award year

2004

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
TRANSGENEX NANOBIOTECH, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
CNWNKZL5QXM1
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): In an effort to develop a better treatment for allergic diseases, including asthma and allergic rhinitis, our goal is to examine the efficacy and safety of chliposome IFN-( gene nanoparticle (CLIN) Therapy. This proposal is based on the two major developments in potential use of gene therapy for asthma: (i) chliposome nanoparticles complexed with a plasmid encoding IFN-( (CIN) when intranasally (i.n.) delivered to the lung, induces significant therapeutic effects in the asthmatic mouse lung without producing substantial IFN-(, and (ii) the efficacy of gene transfer in the lung can be increased with hybrid nanoparticles, comprising chliposome and liposomes (alias: chliposomes, CLIN). Our working hypothesis is that i.n. CLIN therapy is a safe and effective prophylaxis or treatment for asthma. The specific aims of this research project are as follows. In the first aim, we will evaluate to evaluate whether CLIN therapy is effective in a mouse model of inhalant allergy, what dose of CLIN effectively provides protection and whether CLIN therapy will provide protection in a mouse model of chronic allergic asthma. In the second aim, we will evaluate the safety of CLIN-therapy, we plan to assess whether the effective dose produces unwanted adverse effects that can be readily measured. We plan to monitor the expression of inflammatory cytokines and chemokines and acute phase proteins in the nose and lung at 6, 12, 18 and 24 h after administration. The specific questions that the feasibility study will address are: a) whether CLIN administration induces acute local or systemic inflammatory responses and whether it induces any notable toxic effects. The project will be conducted by a group of investigators experienced in the field of allergic disease. The results of the proposed research are expected to advance our knowledge of the mechanisms of asthma and may lead to the development of an effective approach for the prevention and/or treatment of asthma.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

11 SBIR/STTR records share this UEI (2004–2017). Reported award amounts total $3,908,648. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, Department of Defense

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.